sibutramine


Also found in: Dictionary, Wikipedia.
Related to sibutramine: Orlistat, phentermine

sibutramine

 [si-bu´trah-mēn″]
an appetite suppressant used as the hydrochloride salt in treatment of obesity; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

sibutramine

(sə-byo͞o′trə-mĭn, -mēn′)
n.
A drug formerly used in the management of obesity, withdrawn from the US market in 2010 because of its association with an increased risk of heart attacks and strokes.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

sibutramine

A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.

 
Indications
Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).

Adverse effects
Headache, dry mouth, anorexia, constipation.

Contraindications
Concurrent MAOIs, other central appetite suppressants, anorexia nervosa.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

sibutramine

Meridia® Obesity A central, appetite-suppressing agent that blocks reuptake of serotonin and norepinephrine, and, to a lesser extent dopamine; it provides a sensation of fullness from less food, and ↑ metabolism Indications Obese Pts with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 with other factors–eg, HTN, DM, dyslipidemia Cons Sibutramine is a Schedule IV Controlled Substance Adverse effects Headache, dry mouth, anorexia, constipation Contraindications Concurrent MAOIs, other central appetite suppressants, anorexia nervosa. See Obesity.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

si·bu·tra·mine

(si-byū'tră-mēn)
A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

sibutramine

An antiobesity drug that acts on the nervous system in a manner similar to that of Prozac so that the patient is able to feel satisfied with smaller amounts of food. The drug is not recommended for people under 18 and is used for a maximum period of one year. It is prescribed mainly for those with a body mass index (BMI) of 30 or over. Brand name Reductil.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005

Sibutramine

An appetite-suppressing drug that may increase the activity of norepinephrine and serotonin in the brain.
Mentioned in: Weight Loss Drugs
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.

si·bu·tra·mine

(si-byū'tră-mēn)
A serotonin and noradrenaline reuptake inhibitor used to reduce appetite to encourage weight loss.
Medical Dictionary for the Dental Professions © Farlex 2012
References in periodicals archive ?
The company said it will suspend the marketing of Abbott medicines containing sibutramine in all European Union (EU) member countries, as well as Iceland and Norway.
The usual maximum per tablet for sibutramine is 15mg and 20mg for tadalafil.
The health risks posed by these products can be serious; for example, sibutramine can cause high blood pressure, seizures, tachycardia, palpitations, heart attack or stroke.
In teens, the addition of orlistat or sibutramine as an adjunct to lifestyle interventions appeared useful, and should be considered in those who are obese.
Those getting the 12-mg taranabant dose consumed 27% fewer calories, while those who received the sibutramine consumed 20% fewer calories.
Sibutramine (Meridia), used in combination with diet and lifestyle modification, has been demonstrated to promote weight loss and weight maintenance in obese subjects for up to 2 years, (1) and in fact is currently approved by the FDA for 2 years of therapy.
The Italian health ministry ordered a halt to sibutramine sales after it learned that three women, aged 28, 40, and 45, had died after their doctors prescribed the drug for them.
In the recent study, which appeared in the September 19 issue of The Journal of the American Medical Association, nearly 800 obese volunteers received one of three treatments: 15 milligrams of sibutramine once daily, 15 milligrams of sibutramine intermittently (two six-week periods without the drug) or a placebo daily.
"Doctors and patients need to work together to manage this condition and today's guidance provides advice on the contribution which sibutramine can make."
Two small studies looking at relationships between sibutramine and valvular heart disease did not find any increase in valve lesions in patients taking sibutramine compared with placebo.
Some coffee sachets for weight loss are said to contain sibutramine which is an unregistered product with harmful side effects and some of the sexual stimulants available over the net contain sidenafil and sibutramine which are very harmful to people with a history of heart disease, stroke, diabetes, high cholesterol and arrhythmia (irregular heart beat)